<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2012-1120</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-1040</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Современная практика лечения метотрексатом ревматоидного артрита</article-title><trans-title-group xml:lang="en"><trans-title>Current practice of methotrexate treatment for rheumatoid arthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муравьев</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Muravyev</surname><given-names>Yuri Vladimirovich</given-names></name></name-alternatives><email xlink:type="simple">murawyu@mail.ru</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Eloyeva</surname><given-names>N V</given-names></name><name name-style="western" xml:lang="en"><surname>Eloyeva</surname><given-names>N V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Lebedeva</surname><given-names>V V</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedeva</surname><given-names>V V</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Евгений Львович</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E L</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>15</day><month>08</month><year>2012</year></pub-date><volume>50</volume><issue>4</issue><issue-title>№4 (2012)</issue-title><fpage>96</fpage><lpage>97</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Муравьев Ю.В., Eloyeva N.V., Lebedeva V.V., Насонов Е.Л., 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="ru">Муравьев Ю.В., Eloyeva N.V., Lebedeva V.V., Насонов Е.Л.</copyright-holder><copyright-holder xml:lang="en">Muravyev Y.V., Eloyeva N.V., Lebedeva V.V., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/1040">https://rsp.mediar-press.net/rsp/article/view/1040</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;div&gt;&lt;p&gt;Paulus H.E. FDA Arthritis Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma. Arthr Rheum 1986;29:1289-90.&lt;/p&gt;&lt;p&gt;Combe B., Landewe R., Lukas C. et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.&lt;/p&gt;&lt;p&gt;Tugwell P., Bennett K., Gent M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 1987;107:358-66.&lt;/p&gt;&lt;p&gt;Felson D., Anderson J.J., Meenan R.F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthr Rheum 1990;33:1449-61.&lt;/p&gt;&lt;p&gt;Муравьев Ю.В. Практическое применение метотрексата при ревматоидном артрите. Клин фармакол тер 2010;1:91-6.&lt;/p&gt;&lt;p&gt;Насонова В.А., Астапенко М.Г. Клиническая ревматология: Руководство для врачей/АМН СССР. М.: Медицина, 1989;303 с.&lt;/p&gt;&lt;p&gt;Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2005;288 с.&lt;/p&gt;&lt;p&gt;Ревматология: Клинические рекомендации. Под ред. акад. РАМН Е.Л. Насонова. 2-е изд., испр. и доп. М.: ГЭОТАРМедиа, 2010;752 с.&lt;/p&gt;&lt;p&gt;Федеральное руководство по использованию лекарственных средств (формулярная ситема). Вып. XII. М.: Эхо, 2011;956 c.&lt;/p&gt;&lt;p&gt;Furst D.E., Koehnke R., Burmeister L.F., et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16(3):13-20.&lt;/p&gt;&lt;p&gt;Lard L.R., Visser H., Speyer I. et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.&lt;/p&gt;&lt;p&gt;Nell V.P., Machold K.P, Eberl G. et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation><mixed-citation xml:lang="en">&lt;div&gt;&lt;p&gt;Paulus H.E. FDA Arthritis Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma. Arthr Rheum 1986;29:1289-90.&lt;/p&gt;&lt;p&gt;Combe B., Landewe R., Lukas C. et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.&lt;/p&gt;&lt;p&gt;Tugwell P., Bennett K., Gent M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 1987;107:358-66.&lt;/p&gt;&lt;p&gt;Felson D., Anderson J.J., Meenan R.F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthr Rheum 1990;33:1449-61.&lt;/p&gt;&lt;p&gt;Муравьев Ю.В. Практическое применение метотрексата при ревматоидном артрите. Клин фармакол тер 2010;1:91-6.&lt;/p&gt;&lt;p&gt;Насонова В.А., Астапенко М.Г. Клиническая ревматология: Руководство для врачей/АМН СССР. М.: Медицина, 1989;303 с.&lt;/p&gt;&lt;p&gt;Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2005;288 с.&lt;/p&gt;&lt;p&gt;Ревматология: Клинические рекомендации. Под ред. акад. РАМН Е.Л. Насонова. 2-е изд., испр. и доп. М.: ГЭОТАРМедиа, 2010;752 с.&lt;/p&gt;&lt;p&gt;Федеральное руководство по использованию лекарственных средств (формулярная ситема). Вып. XII. М.: Эхо, 2011;956 c.&lt;/p&gt;&lt;p&gt;Furst D.E., Koehnke R., Burmeister L.F., et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16(3):13-20.&lt;/p&gt;&lt;p&gt;Lard L.R., Visser H., Speyer I. et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.&lt;/p&gt;&lt;p&gt;Nell V.P., Machold K.P, Eberl G. et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
